European Commission

Showing 15 posts of 91 posts found.

European Commission approves HIV prevention injection

August 28, 2025
Medical Communications, Research and Development European Commission, Gilead Science, HIV, HIV/AIDS, US Food and Drug Administration, World Health Organisation

The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first twice-yearly injectable medicine approved in …

europe-1395916_640

Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment

July 30, 2025
Medical Communications, Research and Development European Commission, Oncology, Sanofi, Sarclisa, european union, multiple myeloma

Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and …

Biocon Biologics gains EU approval for bone health therapies

July 4, 2025
Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer

Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma

June 24, 2025
Research and Development Committee for Medicinal Products for Human USE, EU, European Commission, European Medicines Agency, German-speaking Myeloma Multicenter Group, Oncology, Sanofi, blood cancer, monoclonal antibody

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s Sarclisa (isatuximab) for approval in …

Roche’s Evrysdi tablet approved in EU for spinal muscular atrophy

June 5, 2025
Research and Development European Commission, Evrysdi, Neurology, Roche, european union, neuromuscular condition, spinal muscular atrophy (SMA)

Roche has received approval from the European Commission for a new tablet formulation of Evrysdi (risdiplam), marking the first and …

Five Facts about mental health

May 21, 2025
Medical Communications, Medical Education, Research and Development European Commission, Pharmacy, Psychiatry, mental health, mental health condition

32% of people suffer from at least one mental health issue, with daily struggles like financial and job insecurity being …

bowel_cancer_screening

European Commission approves Johnson & Johnson’s Crohn’s disease therapy

May 12, 2025
Market Access, Research and Development, Sales and Marketing Crohn’s disease, European Commission, Gastrointestinal tract, Johnson & Johnson, guselkumab, marketing authorisation

The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnson’s Tremfya (guselkumab) for the treatment of moderately …

1200px-european_flag_in_karlskrona_2011

European Commission launches new Biotech and Biomanufacturing Hub

February 3, 2025
Research and Development Biomanufacturing, Corporate, European Commission, Hub, european union

The European Commission has announced the opening of a new Biotech and Biomanufacturing Hub, supporting start-ups and small- to medium-sized …

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024
Medical Communications Emblaveo, European Commission, Immunology, Pfizer

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) for the treatment of adult …

Pfizer’s Velsipity approved by EC for ulcerative colitis treatment

February 20, 2024
Medical Communications European Commission, Gastrointestinal tract, Pfizer, Velsipity, ulcerative colitis

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) in the European Union (EU). …

EC approves Vertex’s Casgevy for sickle cell disease treatment

February 13, 2024
Medical Communications Casgevy, European Commission, Haematology, Vertex pharmaceuticals, sickle cell disease

Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 …

EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma

December 12, 2023
Medical Communications Elrexfio, European Commission, Oncology, Pfizer, multiple myeloma

Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab) for the treatment of …

Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis

November 20, 2023
Medical Communications Almirall, Dermatology, Ebglyss, European Commission, atopic dermatitis

Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients …

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023
Medical Communications European Commission, Oncology, Orserdu, breast cancer

The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as …

EC approves Roche’s Evrysdi for babies under two months with SMA

August 30, 2023
Research and Development European Commission, Evrysdi, Musculo-skeletal disorder, Roche, spinal muscular atrophy

Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing authorisation in the EU to …

The Gateway to Local Adoption Series

Latest content